Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BEVACIZUMAB BS INTRAVENOUS INFUSION 100MG, 400MG [PFIZER] POST-MARKETING DATABASE STUDY

NCT07527832 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07527832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07527832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BEVACIZUMAB BS INTRAVENOUS INFUSION 100MG, 400MG [PFIZER] POST-MARKETING DATABASE STUDY
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
April 20, 2026
Completion date
May 27, 2026
Enrollment
1,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer